Liver Diseases  >>  pamrevlumab (FG-3019)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pamrevlumab (FG-3019) / FibroGen
NCT01217632: A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection

Terminated
2
114
RoW
FG-3019, Placebo, Entecavir, Entecavir Dispersible (generic)
FibroGen
Liver Fibrosis Due to Chronic Hepatitis B Infection
06/15
06/15

Download Options